Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)
- Conditions
- Interventions
- First Posted Date
- 2022-06-10
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 582
- Registration Number
- NCT05413369
- Locations
- 🇨🇳
Investigational Site Number : 1560025, Harbin, China
🇨🇳Investigational Site Number : 1560008, Baotou, China
🇨🇳Investigational Site Number : 1560001, Beijing, China
SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM
- Conditions
- Interventions
- First Posted Date
- 2022-06-06
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 531
- Registration Number
- NCT05405166
- Locations
- 🇺🇸
Arizona Oncology Associates, PC - HAL- Site Number : 8400015, Prescott Valley, Arizona, United States
🇺🇸Rocky Mountain Cancer Centers, LLP- Site Number : 8400021, Aurora, Colorado, United States
🇺🇸Mayo Clinic- Site Number : 8400008, Jacksonville, Florida, United States
Postmarketing Surveillance Study for Quadrivalent Influenza Vaccine (VaxigripTetra Inj.) in Subjects Aged 3 Years Old and Above
- Conditions
- First Posted Date
- 2022-06-06
- Last Posted Date
- 2022-06-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 675
- Registration Number
- NCT05406180
- Locations
- 🇰🇷
Site 012, Gwangju, Korea, Republic of
🇰🇷Site 004, Incheon, Korea, Republic of
🇰🇷Site 007, Incheon, Korea, Republic of
First-in-human Study of SAR443765 in Healthy Participants and in Asthmatic Participants
- Conditions
- Interventions
- First Posted Date
- 2022-05-09
- Last Posted Date
- 2023-04-12
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 36
- Registration Number
- NCT05366764
- Locations
- 🇬🇧
Investigational Site Number :8260001, Belfast, United Kingdom
🇩🇪Investigational Site Number :2760001, Berlin, Germany
Data Analysis of Adult and Pediatric Participants With Acid Sphingomyelinase Deficiency (ASMD) on Early Access to Olipudase Alfa in France
- First Posted Date
- 2022-05-03
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 55
- Registration Number
- NCT05359276
- Locations
- 🇫🇷
Investigational site in France, France, France
Mechanistic Study of the Effect of Itepekimab on Airway Inflammation in Patients With COPD
- Conditions
- Interventions
- First Posted Date
- 2022-04-13
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 50
- Registration Number
- NCT05326412
- Locations
- 🇺🇸
UCLA Medical Center - Harbor- Site Number : 8400006, Torrance, California, United States
🇺🇸National Jewish Health Medical Center- Site Number : 8400012, Denver, Colorado, United States
🇺🇸University of Miami UHealth Tower- Site Number : 8400015, Miami, Florida, United States
Comparative Efficacy of Cemiplimab to Historical Standard of Care in France
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2022-12-13
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 305
- Registration Number
- NCT05302297
Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Mild Hepatic Impairment Compared to Participants With Normal Hepatic Function
- First Posted Date
- 2022-03-17
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 10
- Registration Number
- NCT05283915
- Locations
- 🇺🇸
Nucleus Network-Site Number:8400001, Saint Paul, Minnesota, United States
🇺🇸Clinical Pharmacology of Miami-Site Number:8400002, Miami, Florida, United States
🇺🇸Volunteer Research Group-NOCCR-Site Number:8400003, Knoxville, Tennessee, United States
Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Renal Impairment Compared to Healthy Participants
- First Posted Date
- 2022-03-16
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 24
- Registration Number
- NCT05282030
- Locations
- 🇺🇸
Clinical Pharmacology of Miami-Site Number:8400002, Miami, Florida, United States
🇩🇪Investigational Site Number :2760001, Kiel, Germany
🇺🇸Volunteer Research Group-NOCCR-Site Number:8400003, Knoxville, Tennessee, United States
Systematic Review and Meta-Analysis of Multaq® for Safety in Atrial Fibrillation
- Conditions
- First Posted Date
- 2022-03-15
- Last Posted Date
- 2024-01-09
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 87810
- Registration Number
- NCT05279833
- Locations
- 🇫🇷
Sanofi-Aventis, France, Chilly-Mazarin, France